Paper Review Records
全部论文审稿周期
22 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
113
天
Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine
作者
Ting Shi; Ruicong Xue; Jing Jia; Menghan Liu; Yalan Zhou; Chuanying Geng; Yuan Jian; Ying Tian; Yanru Zhang; Wenjing Li; Lefu Huang; Huixing Zhou; Aijun Liu; Wen Gao; Wenming Chen; Yun Leng; Yin Wu; Hong-Hu Zhu展开收起
作者单位
1. Department of Hematology, Beijing Chao-Yang Hospital, Beijing, China; 2. Institute for Cancer, Chinese Institutes for Medical Research, Beijing, China; 3. Beijing Key Laboratory of Tumor Resistance Mechanism and Clinical Translation, Beijing, China展开收起
78
天
Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study
作者
Lei Ju; Sifeng Gao; JiLei Zhang; Yuyu Liu; Qiang Song; Lin Dong; Yan Guo; Xuemei Qin; Jie Zou; Chenglu Yuan; Yan Shi; Dexiao Kong; Kaifeng Wang; Qiang Li; Donglin Yang; Qingliang Teng; Erlie Jiang; Jun Peng; Guanchen Bai展开收起
作者单位
1. Department of Hematology, The Affiliated Tai’an City Central Hospital of Qingdao University, Taian, China; 2. Department of Hematology, Qilu Hospital of Shandong University, Jinan, China; 3. Department of Hematology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China; 4. Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China; 5. Department of Hematology, The Qilu Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China; 6. Department of Hematology, People’s Hospital of Zhangqiu District, Jinan, China; 7. Department of Hematology, Liaocheng People’s Hospital, Liaocheng City, China; 8. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; 9. State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Department of Hematology, Qilu Hospital of Shandong University, Jinan, China展开收起
65
天
Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
作者
Chenying Li; Hongyan Tong; Huafeng Wang; Yanling Ren; Jiejing Qian; Xinping Zhou; Gaixiang Xu; Liangshun You; Liping Mao; Haitao Meng; Wenjuan Yu; Xingnong Ye; Min Yang; Jian Huang; De Zhou; Wanzhuo Xie; Jie Jin; Yinjun Lou展开收起
作者单位
1. Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China; 2. Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China; 3. Zhejiang Provincial Clinical Research Center For Hematological disorders, Hangzhou, PR China; 4. Zhejiang University Cancer Center, Hangzhou, PR China展开收起
119
天
Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes
作者
Masataka Sakashita; Junya Kanda; Keiichiro Hattori; Nobuhiro Hiramoto; Nobuhiro Kanemura; Senji Kasahara; Mitsumasa Watanabe; Satoshi Yoshihara; Michiko Ichii; Nobuo Sezaki; Masaaki Tsuji; Takeshi Maeda; Ko Sasaki; Toshiyuki Kitano; Yasuko Miyahara; Tadakazu Kondo; Mamiko Sakata-Yanagimoto; Akifumi Takaori-Kondo; Seishi Ogawa; Yasuhito Nannya展开收起
作者单位
1. Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 2. Department of Hematology, Kanazawa University Hospital, Kanazawa University, Ishikawa, Japan; 3. Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 4. Department of Hematology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan; 5. Department of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan; 6. Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan; 7. Department of Hematology, Gifu Municipal Hospital, Gifu, Japan; 8. Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan; 9. Department of Hematology, Hyogo Medical University Hospital, Hyogo, Japan; 10. Department of Hematology and Oncology, The University of Osaka Graduate School of Medicine, Osaka, Japan; 11. Department of Hematology, Chugoku Central Hospital, Hiroshima, Japan; 12. Department of Hematology and Immunology, Japanese Red Cross Otsu Hospital, Otsu, Japan; 13. Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan; 14. Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan; 15. Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan; 16. Department of Hematology, Kyoto City Hospital, Kyoto, Japan; 17. Department of Hematology, University of Tsukuba Hospital, Division of Advanced Hemato-Oncology, Tsukuba, Japan; 18. Transborder Medical Research Center, University of Tsukuba, Tsukuba, Japan; 19. Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; 20. Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天